Metal-based nanoplatforms for enhancing the biomedical applications of berberine: current progress and future directions

被引:1
作者
Baidoo, Isaac [1 ]
Sarbadhikary, Paromita [1 ]
Abrahamse, Heidi [1 ]
George, Blassan P. [1 ]
机构
[1] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, POB 17011, ZA-2028 Johannesburg, South Africa
基金
新加坡国家研究基金会; 英国医学研究理事会;
关键词
Berberine; drug delivery; drug targeting; metallic nanoparticles; nanomedicine; natural products; ENDOPLASMIC-RETICULUM STRESS; TYPE-2; DIABETES-MELLITUS; RAT MODEL; PHOTODYNAMIC THERAPY; DELIVERY-SYSTEM; PROTEIN-KINASE; IN-VITRO; NANOPARTICLES; CANCER; COMBINATION;
D O I
10.1080/17435889.2025.2480051
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The isoquinoline alkaloid berberine, a bioactive compound derived from various plants, has demonstrated extensive therapeutic potential. However, its clinical application is hindered by poor water solubility, low bioavailability, rapid metabolism, and insufficient targeting. Metal-based nanoplatforms offer promising solutions, enhancing drug stability, controlled release, and targeted delivery. This review comprehensively explores the synthesis, physicochemical properties, and biomedical applications of metal-based nanocarriers, including gold, silver, iron oxide, zinc oxide, selenium, and magnetic nanoparticles, for berberine delivery to improve berberine's therapeutic efficacy. Recent advancements in metal-based nanocarrier systems have significantly improved berberine delivery by enhancing cellular uptake, extending circulation time, and enabling site-specific targeting. However, metal-based nanoplatforms encounter several limitations of potential toxicity, limited large-scale productions, and regulatory constraints. Addressing these limitations necessitates extensive studies on biocompatibility, long-term safety, and clinical translation. By summarizing the latest innovations and clinical perspectives, this review aims to guide future research toward optimizing berberine-based nanomedicine for improved therapeutic efficacy.
引用
收藏
页码:851 / 868
页数:18
相关论文
共 166 条
[1]  
Abdel-Megeed Rehab M, 2025, Toxicol Rep, V14, P101887, DOI [10.1016/j.toxrep.2024.101887, 10.1016/j.toxrep.2024.101887]
[2]   Graphene Oxide Nanostructures as Nanoplatforms for Delivering Natural Therapeutic Agents: Applications in Cancer Treatment, Bacterial Infections, and Bone Regeneration Medicine [J].
Abouaitah, Khaled ;
Sabbagh, Farzaneh ;
Kim, Beom Soo .
NANOMATERIALS, 2023, 13 (19)
[3]   Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment [J].
Achi, Ijeoma Theresa ;
Sarbadhikary, Paromita ;
George, Blassan P. ;
Abrahamse, Heidi .
CELLS, 2022, 11 (21)
[4]  
Adeleke Bartholomew Saanu, 2024, Heliyon, V10, pe39636, DOI [10.1016/j.heliyon.2024.e39636, 10.1016/j.heliyon.2024.e39636]
[5]  
Alvarado Y, 2019, MATERIALS FOR BIOMEDICAL ENGINEERING: ORGANIC MICRO AND NANOSTRUCTURES, P135, DOI 10.1016/B978-0-12-818433-2.00005-4
[6]   BERBERINE SULFATE - ANTIMICROBIAL ACTIVITY, BIOASSAY, AND MODE OF ACTION [J].
AMIN, AH ;
SUBBAIAH, TV ;
ABBASI, KM .
CANADIAN JOURNAL OF MICROBIOLOGY, 1969, 15 (09) :1067-&
[7]   The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment [J].
An, Yuan ;
Sun, Zhuangzhuang ;
Zhang, Yajuan ;
Liu, Bin ;
Guan, Yuanyuan ;
Lu, Meisong .
CLINICAL ENDOCRINOLOGY, 2014, 80 (03) :425-431
[8]  
Anandalakshmi K, 2021, PLANT ARCH, V21, P2091, DOI [10.51470/plantarchives.2021.v21.s1.345, 10.51470/PLANTARCHIVES.2021.v21.S1.345, DOI 10.51470/PLANTARCHIVES.2021.V21.S1.345]
[9]   Berberine as a photosensitizing agent for antitumoral photodynamic therapy: Insights into its association to low density lipoproteins [J].
Andreazza, Nathalia Luiza ;
Vevert-Bizet, Christine ;
Bourg-Heckly, Genevieve ;
Sureau, Franck ;
Salvador, Marcos Jose ;
Bonneau, Stephanie .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 510 (01) :240-249
[10]  
[Anonymous], 2019, Trends in Maternal Mortality: 2000 to 2017